Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials

Chest

Volumn 152, Issue 2, 2017, Pages 271-281

  Khunger, Monica ^a   Rakshit, Sagar ^a   Pasupuleti, Vinay ^b   Hernandez, Adrian V ^c,d   Mazzone, Peter ^a   Stevenson, James ^a   Pennell, Nathan A ^a   Velcheti, Vamsidhar ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARTFORD HOSPITAL   (United States)

^d UNIVERSIDAD PERUANA DE CIENCIAS APLICADAS   (Peru)

Author keywords

immune related adverse events; immunotherapy; meta analysis; non small cell lung cancer; pneumonitis

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; CD274 PROTEIN, HUMAN; DURVALUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PDCD1 PROTEIN, HUMAN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADVERSE EFFECTS; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; FEMALE; HUMAN; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; META ANALYSIS; MIDDLE AGED; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PNEUMONIA; PROGRAMMED CELL DEATH 1 RECEPTOR; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85027510221     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.04.177     Document Type: Article

References (28)

1. Velcheti, V., Schalper, K.A., Carvajal, D.E., et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94:1 (2014), 107–116.
2. Postow, M.A., Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book, 2015, 76–83.
3. Weber, J.S., Yang, J.C., Atkins, M.B., Disis, M.L., Toxicities of immunotherapy for the practitioner. J Clin Oncol 33:18 (2015), 2092–2099.
4. Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 373:2 (2015), 123–135.
5. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373:17 (2015), 1627–1639.
6. Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N.H., Hodi, F.S., Incidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2:12 (2016), 1607–1616.
7. Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6(7), 2009, e1000100.
8. Higgins, J.P., Altman, D.G., Gøtzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
9. Bauer, T.M., McCleod, M., Chandler, J.C., et al. An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens. J Clin Oncol, 33(15 suppl), 2015, 3013.
10. Socinski, M., Creelan, B., Horn, L., et al. NSCLC, metastaticCheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC. Ann Oncol, 27(suppl 6), 2016 LBA7_PR.
11. Rittmeyer, A., Barlesi, F., Waterkamp, D., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:10066 (2017), 255–265.
12. Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375:19 (2016), 1823–1833.
13. Antonia, S., Kim, S., Spira, A., Ahn, M., Ou, S., Stjepanovic, N., Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non-small-cell lung cancer. J Clin Oncol, 34(15 suppl), 2016, 9029.
14. Verschraegen, C., Chen, F., Spigel, D., et al. Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: safety, clinical activity, and PD-L1 expression [abstract]. J Clin Oncol, 34, 2016, 9036.
15. Rizvi, N.A., Brahmer, J.R., Ou, S.-H.I., et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol, 33(15 suppl), 2015, 8032.
16. Herbst, R.S., Soria, J.-C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:7528 (2014), 563–567.
17. Spigel, D.R., Chaft, J.E., Gettinger, S.N., et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC). J Clin Oncol, 33(15 suppl), 2015, 8028.
18. Herbst, R.S., Baas, P., Kim, D.-W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:10027 (2016), 1540–1550.
19. Besse, B., Johnson, M., Janne, P., et al. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Eur J Cancer 51 (2015), S717–S718.
20. Gulley, J., Rajan, A., Spigel, D., et al. 3090 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: a phase Ib trial. Eur J Cancer, 51, 2015, S629.
21. Nishio, M., Hida, T., Nakagawa, K., et al. Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC). J Clin Oncol, 33(15 suppl), 2015, 8027.
22. Gettinger, S., Rizvi, N.A., Chow, L.Q., et al. Nivolumab monotherapy for first-line treatment of advanced non–small-cell lung cancer. J Clin Oncol 34:25 (2016), 2980–2987.
23. Gettinger, S.N., Horn, L., Gandhi, L., et al. Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer. J Clin Oncol 33:18 (2015), 2004–2012.
24. Rizvi, N.A., Mazières, J., Planchard, D., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:3 (2015), 257–265.
25. Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 372:21 (2015), 2018–2028.
26. Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:10030 (2016), 1837–1846.
27. Xiao, Y., Yu, S., Zhu, B., et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med 211:5 (2014), 943–959.
28. Takahashi, H., Ogata, H., Nishigaki, R., Broide, D.H., Karin, M., Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 17:1 (2010), 89–97.